SCHEMBL293710

SCHEMBL293710

CCC[CH]c1ccc(OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
CYP2A6 P11509 1/20 0.56
KDM4E B2RXH2 4/20 0.48
CYP3A4 P08684 2/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
TRPA1 O75762 1/20 0.47
RELA Q04206 1/20 0.47
CYP1A2 P05177 3/20 0.45
CYP1A1 P04798 3/20 0.45
CYP1B1 Q16678 3/20 0.45
ESR1 P03372 2/20 0.45
AHR P35869 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6052855 0.88 ALDH1A1 (0.52) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL10529611 0.86 ALDH1A1 (0.50) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL7730462 0.84 CNR1 (0.49) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL1004990 0.84 ALDH1A1 (0.62) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL5358981 0.83 ALDH1A1 (0.37) ALDH1A1CYP2A6TSHRTRPA1
SCHEMBL7370494 0.81 ALDH1A1 (0.54) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL7711464 0.81 ALDH1A1 (0.54) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL16877138 0.81 ALDH1A1 (0.54) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL10889497 0.81 ALDH1A1 (0.54) ALDH1A1CYP2A6KDM4ECYP3A4LMNA
SCHEMBL13181157 0.79 KDM4E (0.55) ALDH1A1KDM4ECYP3A4LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2019-01-08 US disclosed
CN-104382924-A N6-substituted adenosine derivative and N6-substituted adenine derivative and application thereof INST MATERIA MEDICA CAMS 2015-03-04 CN disclosed
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 US disclosed
US-8598162-B2 Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-12-03 US disclosed
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-02-21 US disclosed
US-20120328518-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS PIRAMAL IMAGING SA (CH) 2012-12-27 US disclosed
CN-102812033-A N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof INST MATERIA MEDICA CAMS 2012-12-05 CN disclosed
EP-2511283-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-10-17 EP disclosed
EP-2287161-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-05-09 EP disclosed
EP-2287162-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-05-09 EP disclosed
EP-2287162-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders Otsuka Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed
EP-2287161-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders Otsuka Pharmaceutical Co., Limited (JP) 2011-02-23 EP disclosed
EP-2284169-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders Otsuka Pharmaceutical Co., Limited (JP) 2011-02-16 EP disclosed
US-20090264404-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-22 US disclosed
EP-1919907-A2 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-14 EP disclosed
WO-2008047883-A1 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-04-24 WO disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
US-4581372-A ANTIBODY STIMULANTS;IMMUNOLOGY TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1986-04-08 US disclosed
US-4497815-A 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients Ozaki, Shoichiro (JP) 1985-02-05 US disclosed
US-4340543-A ANTICANCER AGENTS, ANTITUMOR AGENTS, IMMUNOSTIMULANTS TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1982-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 ALDH1A1 408/4885CYP2A6 344/4885KDM4E 1270/4885
US-20090264404-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders GRIN2C, GRIN2B, PMP22 ALDH1A1 408/4885CYP2A6 344/4885KDM4E 1270/4885
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof ADORA2A, ADORA3, ADORA1 ALDH1A1 1674/4885CYP2A6 243/4885KDM4E 689/4885
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF ADORA2A, ADORA3, ADORA1 ALDH1A1 1674/4885CYP2A6 243/4885KDM4E 689/4885
US-20120328518-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS KLK3, FOLH1, ACP3 ALDH1A1 3209/4885CYP2A6 4577/4885KDM4E 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.